Danaher's AI Leap: A Digital Pathology Revolution
Update: 2025-10-01
Description
Danaher stock surged over 7% after its Leica Biosystems unit unveiled new AI-powered digital pathology tools, boosting the Aperio Digital Pathology portfolio. This, coupled with other innovations from Danaher companies like Beckman Coulter, signals a strong push into high-tech healthcare that's catching investors' eyes. While still down year-to-date, Danaher's AI advancements and potential easing of drug-pricing regulations are key factors driving market excitement.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
